Anti SARS-CoV-2 RBD mAb (Clone B38), human & mouse isotypes
|Anti-CoV2RBD-c2-hIgG1||Unit size||Cat. code||Docs||Qty||Price|
SARS-CoV-2 Spike RBD monoclonal human IgG1 antibody (Clone B38)
|Anti-CoV2RBD-c2-mIgG2a||Unit size||Cat. code||Docs||Qty||Price|
SARS-CoV-2 Spike RBD monoclonal mouse IgG2a antibody (Clone B38)
You may also need : Anti SARS-CoV-2 RBD mAb (Clone H4), human & mouse isotypes | View more associated products ▼
Specific SARS-CoV-2 Spike-RBD neutralizing recombinant antibody
InvivoGen provides Anti-CoV2RBD-c2-hIgG1 and Anti-CoV2RBD-c2-mIgG2a isotypes, derived from the specific SARS-CoV-2 neutralizing recombinant monoclonal antibody (mAb) originally described as 'clone B38' . They feature:
- The variable region from 'clone B38' that specifically targets the Spike receptor-binding domain (S-RBD) of SARS-CoV-2 
- The human IgG1 or mouse IgG2a constant region
Clone B38 was isolated from a convalescent COVID-19 patient and subsequently, confirmed to specifically neutralize SARS-CoV-2, in vitro, by blocking the interaction between the SARS-CoV-2 S-RBD and the host receptor ACE2 . The interaction between clone B38 and the spike-RBD was further characterized by crystallography, suggesting that the antibody sterically hinders ACE2 binding to SARS-CoV-2 .
Early in the pandemic, a previously characterized SARS-CoV neutralizing mAb (CR3022) against the S-RBD was rapidly found to cross-react with SARS-CoV-2 . However, CR3022 does not neutralize SARS-CoV-2 possibly because, unlike clone B38, it does not target the ACE2 binding motif in the RBD . Interestingly, synergistic neutralization ability was observed when clone B38 was used in combination with a different epitope-targeting antibody (clone H4) identified in the same study . This makes them a potentially promising virus-targeting antibody cocktail for therapeutic and/or vaccine purposes.
InvivoGen's Anti-CoV2RBD-c2 mAbs (clone B38) have been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography, ensuring lot-to-lot reproducibility. Furthermore, Anti-CoV2RBD-c2-hIgG1 and Anti-CoV2RBD-c2-mIgG2a have been functionally validated by ELISA and/or neutralizing assays (see data below). The absence of bacterial contamination has been confirmed by cellular assays.
Of note, InvivoGen also offers Anti-CoV2RBD-c1-hIgG1 and Anti-CoV2RBD-c1-mIgG2a, derived from another SARS-CoV-2 neutralizing mAb (Clone H4) . In-house data suggests that B38 displays better inhibition of HEK-Blue™ hACE2 cell infection by Spike-pseudotyped lentiviral particles, and clone H4 has greater sensitivity for detection by ELISA. However, depending on your application both mAbs may be suitable for the detection of Spike-RBD and neutralization of SARS-CoV-2 infection.
- Detecting the presence of SARS-CoV-2 in culture supernatant and/or in serum (ELISA)
- Flow cytometry binding assays
- Developing neutralizing antibody cocktails against SARS-CoV-2
- Functionally validated by ELISA using a coated Spike-RBD-His fusion peptide
Read our reviews discussing SARS-CoV-2
1. Wu, Y. et al. 2020. A non-competing pair of human neutralizing antibodies block the COVID-19 virus binding to its receptor ACE2. Science 368, 1274-1278.
2. Tian X. et al., 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes & Infections. 9(1):382-385.
3. Yuan M. et al., 2020. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. DOI: 10.1126/science.abb7269.
Validation of binding to SARS-CoV-2 RBD by ELISA. SARS‑CoV-2 Spike-RBD-His fusion peptide (5 μg/ml) was coated onto ELISA plates overnight. A serial dilution of Anti‑CoV2RBD-c2-hIgG1 (red curve) or Anti-βGal-hIgG1 (control antibody; grey curve) was added to the pre-coated plate and incubated for 1 hour. Subsequently, binding was detected with an HRP-labelled anti-hIgG1 antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride). Absorbance was read at 490 nm.
Inhibition of SARS-CoV-2 spike (G614-variant) pseudotyped lentiviral particles to infect human (h)ACE2-expressing cells. Anti-CoV2RBD-c2-hIgG1 (clone B38), Anti‑COV2RBD‑c1‑hIgG1 (clone H4), or a cocktail of both mAbs was incubated with SARS-CoV-2 spike-(G614-variant)-pseudotyped lentiviral particles for 1 hour at 37°C. Following this, HEK-Blue™ hACE2 cells were added and incubated for a further 72 hours. Infection by the pseudotyped particles (GFP-expression) was then measured using flow cytometry. Data are presented as % inhibition compared to the antibody-negative control.
Figure 1: Validation of binding to SARS-CoV-2 RBD by ELISA.
SARS‑CoV-2 Spike-RBD-His fusion peptide (5 μg/ml) was coated onto ELISA plates overnight. A serial dilution of Anti‑CoV2RBD-c2-mIgG2a (red curve) or Anti-β-Gal-mIgG2a (control antibody; grey curve) was added to the pre-coated plate and incubated for 1 hour. Subsequently, binding was detected with an HRP-labelled anti-mIgG2a antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride). Absorbance was read at 490 nm.
Specificity: SARS-CoV-2 Spike RBD
Source: CHO cells
Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.
- hIgG1: purified by affinity chromatography with protein G
- mIgG2a: purified by affinity chromatography with protein A
- The complete sequence of each antibody construct has been verified.
- Antibody binding has been validated by ELISA using a coated Spike-RBD-His fusion peptide.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.
- 100 µg purified antibody, azide-free, and lyophilized
The product is shipped at room temperature.
Store lyophilized antibody at -20 °C.
Lyophilized product is stable for at least 1 year.Back to the top